

# Zlatko Fras

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7392521/publications.pdf>

Version: 2024-02-01

56  
papers

22,588  
citations

257450

24  
h-index

155660

55  
g-index

57  
all docs

57  
docs citations

57  
times ranked

22963  
citing authors

#	ARTICLE	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018, 39, 3021-3104.	2.2	6,826
2	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 111-188.	2.2	4,871
3	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
4	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. <i>European Heart Journal</i> , 2021, 42, 3227-3337.	2.2	2,517
5	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Heart Journal</i> , 2018, 39, 763-816.	2.2	2,305
6	European Society of Cardiology: Cardiovascular Disease Statistics 2019. <i>European Heart Journal</i> , 2020, 41, 12-85.	2.2	690
7	Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2015, 1, 1-23.	0.9	311
8	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	2.8	296
9	Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Nutrition Reviews</i> , 2017, 75, 731-767.	5.8	238
10	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.	2.8	216
11	Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. <i>Archives of Medical Science</i> , 2017, 5, 965-1005.	0.9	206
12	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). <i>Atherosclerosis</i> , 2018, 277, 234-255.	0.8	163
13	Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 935-955.	2.4	117
14	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020, 41, 4245-4255.	2.2	117
15	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. <i>Atherosclerosis Supplements</i> , 2016, 22, 1-32.	1.2	90
16	Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2019, 143, 1-16.	7.1	90
17	Universal screening for familial hypercholesterolemia in children: The Slovenian model and literature review. <i>Atherosclerosis</i> , 2018, 277, 383-391.	0.8	73
18	Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. <i>Pharmacological Research</i> , 2020, 158, 104891.	7.1	62

#	ARTICLE	IF	CITATIONS
19	Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). <i>Pharmacological Research</i> , 2021, 166, 105499.	7.1	62
20	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021, 78, 421-433.	2.8	58
21	Prioritizing research challenges and funding for allergy and asthma and the need for translational researchâ€”The European Strategic Forum on Allergic Diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2064-2076.	5.7	39
22	Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1212-1219.	1.8	33
23	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , 2019, 39, e1-e8.	1.2	31
24	HDL and cancer - causality still needs to be confirmed? Update 2020. <i>Seminars in Cancer Biology</i> , 2021, 73, 169-177.	9.6	29
25	Exercise training in adults with repaired tetralogy of Fallot: A randomized controlled pilot study of continuous versus interval training. <i>International Journal of Cardiology</i> , 2018, 255, 37-44.	1.7	28
26	Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 328-339.	1.8	27
27	Moderate-pain versus pain-free exercise, walking capacity, and cardiovascular health in patients with peripheral artery disease. <i>Journal of Vascular Surgery</i> , 2019, 70, 148-156.	1.1	24
28	Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in) Tj ETQq0 0 0 rgBT /Overlock 10 2008, 24, 2467-2476.	1.9	21
29	Regular exercise behaviour and intention and symptoms of anxiety and depression in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 84-91.	1.8	20
30	Left ventricular functional recovery of infarcted and remote myocardium after ST-segment elevation myocardial infarction (METOCARD-CNIC randomized clinical trial substudy). <i>Journal of Cardiovascular Magnetic Resonance</i> , 2020, 22, 44.	3.3	19
31	Moderate-dose atorvastatin improves arterial endothelial function in patients with angina pectoris and normal coronary angiogram: a pilot study. <i>Archives of Medical Science</i> , 2017, 4, 827-836.	0.9	18
32	Influence of the Quantity of Aortic Valve Calcium on the Agreement Between Automated 3-Dimensional Transesophageal Echocardiography and Multidetector Row Computed Tomography for Aortic Annulus Sizing. <i>American Journal of Cardiology</i> , 2018, 121, 86-93.	1.6	18
33	Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. <i>Atherosclerosis</i> , 2022, 348, 25-35.	0.8	18
34	Effect of Early Metoprolol During ST-Segment Elevation Myocardial Infarction on Left Ventricular Strain. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1188-1198.	5.3	15
35	On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management. <i>Archives of Medical Science</i> , 2021, 17, 954-964.	0.9	15
36	Five-Year Outcomes and Prognostic Value of Feature-Tracking Cardiovascular Magnetic Resonance in Patients Receiving Early Prereperfusion Metoprolol in Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2020, 133, 39-47.	1.6	14

#	ARTICLE	IF	CITATIONS
37	Peripheral arterial disease and intermittent claudication in coronary heart disease patients. <i>International Journal of Cardiology</i> , 2021, 322, 227-232.	1.7	9
38	Socioeconomic characteristics of patients with coronary heart disease in relation to their cardiovascular risk profile. <i>Heart</i> , 2021, 107, 799-806.	2.9	9
39	The effect of submaximal exercise on fibrinolysis. <i>Blood Coagulation and Fibrinolysis</i> , 2004, 15, 227-234.	1.0	8
40	NT-proBNP is a weak indicator of cardiac function and haemodynamic response to exercise in chronic heart failure. <i>ESC Heart Failure</i> , 2019, 6, 449-454.	3.1	8
41	Exercise capacity improvement after cardiac rehabilitation following myocardial infarction and its association with long-term cardiovascular events. <i>European Journal of Cardiovascular Nursing</i> , 2022, 21, 76-84.	0.9	8
42	CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities. <i>Metabolites</i> , 2021, 11, 857.	2.9	8
43	Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry. <i>Journal of Hypertension</i> , 2019, 37, 2015-2023.	0.5	7
44	The Use of Aspirin in Contemporary Primary Prevention of Atherosclerotic Cardiovascular Diseases Revisited: The Increasing Need and Call for a Personalized Therapeutic Approach. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 139-151.	2.2	6
45	Potential for optimizing management of obesity in the secondary prevention of coronary heart disease. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, , .	4.0	5
46	Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective. <i>Metabolites</i> , 2021, 11, 611.	2.9	5
47	Results of CINDI Health Monitor surveys in Slovenia as a tool for development of effective healthy nutrition and physical activity intervention programmes. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2006, 14, 110-118.	1.6	4
48	Increased cardiovascular risk associated to hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities. <i>Anatolian Journal of Cardiology</i> , 2019, 23, 60-69.	0.9	4
49	Vascular Function in Patients After Myocardial Infarction: The Importance of Physical Activity. <i>Frontiers in Physiology</i> , 2021, 12, 763043.	2.8	4
50	Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes) <i>Tj ETQq0.0 0 rgBT3Overlock</i>	1.0	4
51	Have We Learnt all from IMPROVE-IT? Part II. Subanalyses of the Effects of Ezetimibe Added to Statin Therapy on Selected Clinical and Laboratory Outcomes, Cost-Effectiveness, Guidelines, and Clinical Implications. <i>Current Vascular Pharmacology</i> , 2021, 19, 469-486.	1.7	3
52	New, 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases â€“ a truly strong base for the major â€“paradigm shiftâ€™ in clinical practice?. <i>Anatolian Journal of Cardiology</i> , 2019, 22, 214-218.	0.9	3
53	Current Choice for LDL-C Lowering in High-Risk CVD Patients Intolerant to Statins. <i>Current Vascular Pharmacology</i> , 2021, 19, 398-402.	1.7	2
54	Complete Revascularization and Survival in STEMI. <i>Global Heart</i> , 2021, 16, 64.	2.3	2

#	ARTICLE	IF	CITATIONS
55	Prognostic Impact of Nonobstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography. <i>Angiology</i> , 2021, 72, 749-753.	1.8	1
56	Do we have a unified consensus on antithrombotic management of PAD?. <i>International Angiology</i> , 2021, 40, 229-239.	0.9	1